Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 2/2017

01-05-2017 | Case based reviews

Anti-Ri antibody associated small cell lung carcinoma

Authors: C. G. O’Leary, J. E. Battley, S. O’Reilly

Published in: Irish Journal of Medical Science (1971 -) | Issue 2/2017

Login to get access

Abstract

Background

Anti-neuronal antibody Anti-Ri may be positive in patients with paraneoplastic syndrome associated with certain cancer subtypes. Anti-Ri positivity has been associated with breast, gynaecological and small cell lung cancers.

Case report

A 69 year-old female presented with a sudden decline in cognition requiring hospital admission. She had an extensive medical history including a significant smoking history and bipolar affective disorder for which she was prescribed lithium. Her cognitive decline was initially attributed to diabetes insipidus secondary to lithium therapy. She made a slow but gradual recovery with treatment. Additional investigations revealed positive Anti-Ri antibody. An occult malignancy screen identified enlarged aorto-pulmonary lymph nodes of indeterminate significance. Following discussion at the regional cardiothoracic multidisciplinary team meeting, three monthly surveillance scans were performed. At month 6 an increase in thoracic adenopathy was seen however endobronchial ultrasound guided biopsy failed to identify malignant cells. Further progression with new supraclavicular adenopathy was seen on repeat imaging 6 months later. A fine need aspirate of an enlarged supraclavicular lymph node was diagnostic for small cell lung cancer, staged as TxN3M0 on positron emission tomography. The patient went on to receive sequential chemo-radiotherapy with a truncated course of carboplatin and etoposide and 50 Gy/25 fractions of thoracic radiotherapy.

Discussion

This case suggests that a positive Anti-Ri antibody may predate the development of clinical or radiological evidence of malignancy. If Anti-Ri positivity is identified, strong consideration should be given to screening for malignancy and regular surveillance. This approach may lead to earlier diagnosis and a better outcome for these patients.
Literature
3.
go back to reference White D et al (2010) Paraneoplastic limbic encephalitis in an elderly patient with small cell lung carcinoma. Ulster Med J 79(1):22–24PubMedPubMedCentral White D et al (2010) Paraneoplastic limbic encephalitis in an elderly patient with small cell lung carcinoma. Ulster Med J 79(1):22–24PubMedPubMedCentral
4.
go back to reference Lugue FA et al (1991) Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 29(3):241–251CrossRef Lugue FA et al (1991) Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 29(3):241–251CrossRef
5.
go back to reference Moll JW et al (1990) Diagnostic value of anti-neuronal antibodies for paraneoplastic disorders of the nervous system. J Neurol Neurosurg Psychiatry 53(11):940–943CrossRefPubMedPubMedCentral Moll JW et al (1990) Diagnostic value of anti-neuronal antibodies for paraneoplastic disorders of the nervous system. J Neurol Neurosurg Psychiatry 53(11):940–943CrossRefPubMedPubMedCentral
6.
go back to reference Rees J (2004) Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. J Neurol Neurosurg Psychiatry 75(2):ii43–ii50PubMedPubMedCentral Rees J (2004) Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. J Neurol Neurosurg Psychiatry 75(2):ii43–ii50PubMedPubMedCentral
Metadata
Title
Anti-Ri antibody associated small cell lung carcinoma
Authors
C. G. O’Leary
J. E. Battley
S. O’Reilly
Publication date
01-05-2017
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 2/2017
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-016-1402-1

Other articles of this Issue 2/2017

Irish Journal of Medical Science (1971 -) 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.